Purchase this article with an account.
Netan Choudhry; Anti-VEGF treatment of CNVM Secondary to Chronic Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6383.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to examine the efficacyof intravitreal Anti-VEGF therapy on the treatment of choroidal neovascular membranes secondary to chronic central serous retinopathy.
A retrospective review of 5 eyes presenting with chronic central serous retinopathy treated with monthly anti-VEGF 0.5mg (bevacizumab or ranibizumab). Patients underwent baseline fluorescein angiography, OCT with clinical examination. At each monthly visit patient BCVA was measured in conjunction with OCT to measure response. Follow-up time ranged from 3-12 months.
All patient presented with subretinal hemorrhage and leakage on fluorescein angiography upon presentation. Mean visual acuity improvement after 3 months of treatment was + 10 letters and 12 letters at 6 months. All eyes demonstrated improvement of OCT features with complete resolution of subretinal fluid in all eyes by 6 months. Intraretinal cystic fluid and shallow PED"s were present in 4 eyes at 6 months.
Intravitreal Anti-VEGF therapy demonstrated improvement in best-corrected ETDRS visual acuity in all patients and OCT abnormalities, particularly subretinal fluid. Intravitreal Anti-VEGF therapy is an effective treatment for choroidal neovascular membranes secondary to Chronic Central Serous Retinopathy.
This PDF is available to Subscribers Only